The BAIAP2 Pathway Regulates Proliferation and Migration in Medulloblastoma.
The study reports that BAIAP2 is overexpressed in medulloblastoma, that its knockdown reduces medulloblastoma-cell proliferation and migration, and that the BAIAP2-binding compound NSC678917 produces similar cellular effects.
Open original publication →What the AI sees
The study reports that BAIAP2 is overexpressed in medulloblastoma, that its knockdown reduces medulloblastoma-cell proliferation and migration, and that the BAIAP2-binding compound NSC678917 produces similar cellular effects.
Research significance
The supplied evidence identifies BAIAP2 as a candidate medulloblastoma dependency and NSC678917 as a BAIAP2-binding preclinical hit; it is reasonable—but not yet demonstrated—to hypothesize that pharmacologic disruption of the BAIAP2 pathway could limit tumor growth or dissemination in vivo.
Source abstract
Medulloblastoma (MB) is the most common malignant pediatric brain tumor, with high rates of recurrence and resistance to standard-of-care therapy. Therefore, novel drugs are needed that target different aspects of MB biology, including the proliferative and migratory properties of tumor cells. Using bioinformatic approaches, we demonstrate that the cytoskeletal scaffolding protein BAIAP2 is differentially expressed in MB compared to non-tumor brain cells, and that it is overexpressed in MB and metastatic MB tissue compared to normal cerebellum. BAIAP2 interacts with the Rho GTPases CDC42 and RAC1, which have known roles in migration and proliferation in multiple cell types. We demonstrate that BAIAP2 knockdown reduces migration and proliferation of MB cells. To characterize the BAIAP2 pathway further, we developed a small molecule screen using surface plasmon resonance (SPR) for compounds that bind BAIAP2. We discovered that the small molecule NSC678917 binds to BAIAP2 and inhibits MB cell proliferation and migration. Collectively, our studies suggest that the BAIAP2 pathway is a novel point of therapeutic intervention in MB.